Study #2023-0289
Phase I/Ib study of adoptive NK expressing an affinity-enhanced T-cell receptor (TCR) reactive against the NY-ESO-1-specific cord blood-derived NK cells (NY-ESO-1 TCR/IL-15 NK) in conjunction with lymphodepleting chemotherapy for the management of advanced synovial sarcoma and myxoid/round cell liposarcoma
MD Anderson Study Status
Enrolling
Treatment Agent
Fludarabine phosphate, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide
Description
The goal of this clinical research study is to find a recommended dose of donated NK cells that can be given along with chemotherapy to patients with advanced cancers. The safety and effects of this therapy will also be studied.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Synovial Sarcoma, Myxoid/Round Cell Liposarcoma
Study phase:
Phase I
Physician name:
John Livingston
Department:
Sarcoma Medical Oncology
For general questions about clinical trials:
1-866-491-0980
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.